Parenteral Drug Association
Connecting People, Science and Regulation ®
by: Oliver Stauffer, PTI
by: Amisha Patel
by: Michael Anyadiegwu, PhD, Renske Hesselink, PhD, and Ingrid Kromann
James Tucker, Ecolab Life Sciences
Alessandro Morandotti, Ompi
David Hussong, PhD, Eagle Analytical Services, Radhakrishna Tirumalai, PhD, USP, Edward Tidswell, PhD, Merck, and Donald Singer, GSK
Rebecca Stauffer, PDA
Vladislav Shestakov, Russian State Institute of Drugs and Good Practices, and Elizabeth Meyers, Amgen
Vito Pirrera and John Jordon, Vantage Solutions
Darryl Peterson, Antares Vision
Rebecca Stauffer and Aneeta Mathur-Ashton, PDA
Oliver Stauffer, PTI
Mark Crawford
Anthony Newcombe, PhD, PAREXEL Consulting and Siegfried Schmitt, PAREXEL Consulting
David Chesney, DL Chesney Consulting
Jennifer Farrington, PhD, Associates of Cape Cod, and Friedrich von Wintzingerode, PhD, Roche Diagnostics GmbH
Stephan Krause, PhD, AstraZeneca Biologics, and Jens Schletter, PhD, Novartis
Toni Manzano, PhD, PDA Knowledge Management Roadmap Task Force
Naheed Sayeed-Desta, Apotex, Ajay Babu Pazhayattil, and Ivy Louis, Vienni Training and Consulting LLP
Victoria Hayes, ICQ
Siegfried Schmitt, PAREXEL Consulting and Anthony Newcombe, PhD, PAREXEL Consulting
Ursula Busse, PhD MBA, Tigen Pharma and Melissa Seymour, MBA
Frank Panofen, Particle Measuring Systems
Barbara Rellahan, Amgen
Martijn van der Plas, PhD, Medicines Evaluation Board, and Michael De Felippis, PhD, Eli Lilly
Lina Genovesi
Dominick DeGrazio, PhD, Janssen R&D, LLC
Austin Caudle, IQVIA
James McCaw, West Pharmaceutical Services, Inc.
Emanuela Lacana, PhD, U.S. FDA
John Geigert, PhD, BioPharmaceutical Quality Solutions
Joshua Eaton, PDA
Claudia Heinl, PhD, Schott
Martin VanTrieste
Tony Pavell, Fresenius Kabi
Pieter-Jan Van Bockstal, Ghent University, Jos Corver, RheaVita, and Thomas De Beer, Ghent University
2018 PDA Annual Meeting speakers
Cristiana Campa, GSK Vaccines, and Nancy Cauwenberghs, MSD
Stephan Krause, PhD, AstreZeneca Biologics, Emanuela Lacana, PhD, U.S. FDA, Jens Schletter, PhD, Sandoz, and Rebecca Stauffer, PDA
Polly Hanff, Saint-Gobain Performance Plastics
Frithjof Holtz, Merck KGaA, Darmstadt, Germany
Daniel Kramer, Robert Schaut, PhD, Ela Bakowska, Misty Riesbeck, Alex Thomas, Steven Tietje, Corning Incorporated
Hal Baseman, ValSource, and Brett Duersch, Merck and Co.
Frank Panofen, PhD, Particle Measuring Systems
Tia Bush, Amgen
Michele D’Alessandro, Merck & Co., and Aaron Goerke, F. Hoffmann-La Roche Ltd.
Roger Asselta, Genesis Packaging Technologies
Samuel Dorey, Sartorius
Richard Denk, SKAN AG , Andreas Flueckiger, MD, Roche Group , Hirokazu Kisaka, Takeda Pharmaceutical Company , Reinhold Maeck, Boehringer Ingelheim , Lars Restetzki, PhD, Roche Group , Andreas Schreiner, PhD, Novartis , and Rico Schulze, Landesdirektion Sachsen
Napoleon Monroe, New Directions Consulting
David Hubmayr, CSL Behring
Ursula Busse, PhD, Novartis
J. Martin Bultmann
R. J. Filannino, Alice Redmond, and Richard Tree, Commissioning Agents
Crystal Kraft, PhD, West Pharmaceutical Services, Inc., and Claudia Heinl, PhD, Schott AG
Mousumi Paul and Scott Hooper, Merck Sharp and Dohme Corp.
Mathias Romacker, Pfizer, Conference Scientific Program Planning Committee, with Rebecca Stauffer, PDA
Diane Paskiet, West, and Ronald Iacocca, PhD, Eli Lilly and Company
John D. Ayres, MD, Eli Lilly and Company
Guenther Gapp, Independent Consultant
Jennifer Farrington, PhD, Associates of Cape Cod, Inc.
Scott Kaszuba, Pfizer
Jim Polarine Jr., MA, STERIS Corporation and David Shields, STERIS
Anders Vinther, Sanofi Pasteur, Emma Ramnarine, Genentech/Roche, Kevin O’Donnell, Irish Health Products Regulatory Authority
Austin Caudle, Metabolon, Inc.
Edward Tidswell, PhD, Merck, and Walid El Azab, Steris
Gilberto Dalmaso, PhD, Particle Measuring Systems
Fabio De Martino, PDA West Coast Chapter President-elect, F. Hoffmann La-Roche, and Beth C. Keij, Sangamo Therapeutics
Rick Watson, Merck & Co., Inc.
Sabrina Restrepo, PhD, Merck, and Christopher J. Smalley, PhD, ValSource
Marsha Steed (Hardiman), ValSource
Kurt Brorson and Sau L. Lee, U.S. FDA
Jacqueline Kunzler, PhD, Baxter International Inc.
Stephanie Gaulding, DPS Engineering
Rafik H. Bishara, PhD, Eli Lilly and Company (retired) and Erik van Asselt, PhD, MSD
Robert A. Schaut, PhD, and W. Porter Weeks, Corning Incorporated
Roy Cherris, Bridge Associates International
Ursula Busse, PhD, Novartis, and Steffen Gross, Paul-Ehrlich-Institut
Mathias Romacker, Pfizer, and Hanns-Christian Mahler, Lonza
Nrupa Patel, Teligent Pharma Inc., and Sandip Patel, Navinta LLC
Wendy Saffell-Clemmer, Baxter Healthcare
Anders Vinther, Sanofi Pasteur; Emma Ramnarine, Genentech; co-chairs PDA Post Approval Change: Innovation for Availability of Medicines (PAC iAM) Task Force
Stefan Kleinmann, PhD, METALL + PLASTIC GmbH , Matthias Scheu, METALL + PLASTIC GmbH , Roland Schuhwerk, Cilag AG , and Volker Baur, Cilag AG
Susan Schniepp, Regulatory Compliance Associates, and Steven Mendivil, Amgen